-
4.82025 Impact Factor
-
56/183Immunology (Rank by Impact Factor)
-
7.82025 CiteScore
Latest impact metrics for Antibody Therapeutics
We are pleased to share the latest impact metrics for Antibody Therapeutics. The journal was recently awarded a CiteScore™ (Scopus) of 7.8, an Impact Factor of 4.8 (Journal Citation Reports™), and over 207,842 full-text downloads in 2025. We invite you to explore the latest breakthroughs and consider the journal as the next outlet for your work.
Learn more about why the journal is the perfect home for your research
Call for Proposals: Antibody Engineering-Based Protein Degraders
Antibody Therapeutics invites proposals that focus on antibody-based protein degraders and advance the discovery, engineering, development, and clinical translation of next-generation targeted degradation technologies.
Learn more

Reasons to submit
Antibody Therapeutics offers rapid peer review, global visibility through full open access, and a platform that maximizes the reach and impact of your research.
Explore more author benefits

Special Collections
Explore special collections from Antibody Therapeutics, highlighting the latest research on important topics in the field.
- Formulation of Antibody-Based Therapeutics
- Antibody–Drug Conjugates in Cancer and Beyond
- AntibodyPlus™: Therapeutics comprising antibody and effector modules
- Bispecific Antibody CMC
- Antibody-targeted Cytotoxic agents – Immunotoxins and ADCs
Browse the special collections

Papers of the Year Award 2025
Antibody Therapeutics is delighted to announce the inaugural Antibody Therapeutics Papers of the Year Award, recognizing exceptional articles published in the previous year. The awards will be officially presented at the Antibody Therapeutics Symposium on May 9, 2026.
View the winning papers

High-Impact Research Collection
Explore a collection of the most read, most cited, and most discussed articles published in Antibody Therapeutics in recent years. Discover what has caught the attention of your peers.
Browse the collection
ChAbS members publish OA at a discounted cost
ChAbS members: Submit your research to Antibody Therapeutics and receive 25% off the Article Processing Charge. Benefit from open access, which ensures greater visibility, increased citations, and enhanced impact. Not a member? Click here to learn more about taking advantage of membership and APC discounts.

Never miss the latest research
As a dedicated researcher or enthusiast in the field of antibody therapeutics, you won't want to miss out on the latest breakthroughs and discoveries.
Learn more & sign up for email alerts
Get ahead with advance articles
Stay at the forefront of research with our latest articles before they appear in the latest issue. Explore cutting-edge findings and insights as soon as they’re available.
Read now
More from ChAbS

About the society
Antibody Therapeutics is the official journal of the ChAbS . The mission of ChAbS is to bring together industry leaders, healthcare providers, researchers, academics, and investors to connect and collaborate on the discover, development, manufacturing, and marketing of therapeutic antibodies.
Learn more
Become a member
ChAbS membership comes with a host of benefits including networking opportunities, access to the society's exclusive WeChat group, discounted meeting registration fees, and educational webinars.
Join today
ChAbS Events
ChAbS brings together the world to accelerate the development and marketing of therapeutic antibodies.
Events
